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INTRODUCTION
Mycobacterium celatum is a nonphoto-
chromogenic mycobacterial species,
phenotypicallysimilartoM. aviumandM. xenopi,
described for the first time less than a decade
ago.1 Several reports exist in the literature
establishing this organism as a convincing
pathogenamongHumanImmunodeficiencyVirus
(HIV) seropositive patients.2-9 However, there is
little evidence of its pathogenicity among
individuals whose immune function is not
profoundly impaired. We describe an episode of
pulmonary infection withM. celatum in apatient
whose clinical syndrome was compatible with a
diagnosisofmycobacterialdiseaseinwhomthere
was no evidence of severe immune deficiency.
CASE REPORT
A 79-year-old man presented to hospital
complaining of increasing dyspnoea over the
preceding two weeks accompanied by drenching
night sweats, general malaise and approximately
10kg weight loss during the preceding twelve
weeks. Hereported apriorhistoryoftuberculosis
affecting a cervical lymph node which had been
resected 30 years previously. He also suffered
from chronic obstructive pulmonary disease
(COPD) having smoked40cigarettes perday for
60 years. His medications were oral salbutamol,
inhaled salbutamol and inhaledbeclomethasone.
He was found to be pyrexial on admission and
continued to have fevers for seven days.
Oropharyngeal mucocutaneous candidiasis was
present. There were no abnormal findings on
examination of the respiratory, nor any other,
system. Analysis of peripheral blood revealed a
leucocytosis with predominant neutrophilia. On
the chestradiograph there was evidence of acute
patchy consolidation with pleural thickening in
the upper lobe of the right lung; there was also
minor patchy consolidation affecting the upper
lobe of the left lung. (Figure)
Initial empiric therapy was with intravenous
coamoxiclav and clarithromycin for six days.
Sputum direct microscopy findings of acid-fast
Fig. Chest Radiograph
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bacilli (AFB) resultedin achange tothepatient's
empiric therapy; isoniazid, rifampicin,
pyrazinamide and ethambutol were introduced.
The fever settled after 48-hours with later
resolution ofthe leucocytosis following ten days
of this regimen. When the identity of the isolate
and its antimicrobial sensitivities became
available therapy was changed to rifampicin,
ethambutol and clarithromycin. This patient's
symptoms of sweats and malaise have improved
since this therapy was introduced; however he
remainsdyspnoeicasaresultofcontinuingCOPD.
MICROBIOLOGICAL INVESTIGATIONS
Three sets ofblood cultures, processed using the
BacT/Alert (Organon Teknica Corporation,
Durham, NC, USA) system, were negative with
the exception of a nonsignificant isolate of
Propionibacteriumsp. Fivespecimensofsputum
were processed routinely for typical bacterial
pathogens yielding only Candida sp. on two
occasions in keeping with the clinical finding of
mucocutaneous candidiasis. Atypical bacterial
and viral respiratory pathogen serology was
negative and urine culture failed to produce any
pathogen. Eight specimens of sputum from the
patient were handled by the mycobacteriology
laboratory; although AFB were visualised on
direct microscopy of only three of these, M.
celatum was cultured in all instances. The search
foranalternativepathogenwasconductedwithout
success. The isolates had not been identifiable to
speciesleveleitherbyroutinephenotypicmethods
orusing commercial DNA geneprobe kits forM.
tuberculosis and M. avium intracellulare.
Molecular identification was performed by PCR
amplification and sequencing of a region of the
16S rRNA gene, using a previously described
method,10withmodificationoftheforwardprimer
to PSL, as described by Campbell et al.11 Upon
anaylsis using BLAST alignment software
(http://www.blast.genome.ad.jp/), the isolates
were identifiedasM. celatumwith557/557 bases
called (100% homology). This sequence has
subsequently been deposited in GenBank with
the Accession number AF433135.
DISCUSSION
M. celatum, first described in 1993,' is an
established pathogen among seriously
immunocompromised HIV-seropositive
individuals 2-9 and belongs to the group of
mycobacteria other than Tuberculosis (MOTT).
Interestingly, its role in disease among other
populations is less well described. The case we
outline represents the first isolation of this
organism in Northern Ireland and, of note, this
patient had no markers of severe immune
deficiency. Although HIV serology was not
soughtseropositivity, inthecontextofthisman's
risk profile, seems extremely unlikely.
Itisacceptedthattheidentification ofM. celatum
in routine practice is difficult since it is
phenotypically similar to M. avium and M.
xenopi 1-s and, in addition, has been reported to
cause false positive results with M. tuberculosis
DNA-probe kits.7' 12, 13Correctidentification is of
importance since M. celatum is known to have
low in-vitro susceptibilities to many
antituberculous drugs 2,3, 14 although the
correlation between these and clinical outcome
remains unclear. Furthermore, as evidence
developsandtherapeuticoptionsincrease, therapy
forM. celatum infection maycome todifferfrom
therapy for other MOTT.
ThisreportmayservetohighlightthatM. celatum
can cause pulmonary infection in populations
otherthanprofoundlyimmunocompromisedHIV-
seropositive patients.
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